Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib
- 254 Downloads
Recently, pneumatosis intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on pneumatosis intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to pneumatosis intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that pneumatosis intestinalis is a probable class-effect of anti-VEGF agents.
KeywordsVascular Endothelial Growth Factor Bevacizumab Sorafenib Celiac Disease Sunitinib
Acknowledgments of research support for the study: none.
- 7.Steeghs N, Rabelink TJ, Op’t Roodt J, et al (2009) Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann OncolGoogle Scholar
- 15.Loriot Y, Perlemuter G, Malka D et al (2008) Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clinical Practice 5:268–278Google Scholar